Ubisoft has cancelled six games, including the long-awaited Prince of Persia: The Sands of Time remake, in a… The post Ubisoft shuts down Prince of Persia remakeUbisoft has cancelled six games, including the long-awaited Prince of Persia: The Sands of Time remake, in a… The post Ubisoft shuts down Prince of Persia remake

Ubisoft shuts down Prince of Persia remake, 5 others as it resets its business

  • Six other Ubisoft games were cancelled
  • Two studios closed
  • Shares drop sharply after the announcement

Ubisoft has cancelled six games, including the long-awaited Prince of Persia: The Sands of Time remake, in a sweeping reset that signals how tough things have become for big game studios.

The French publisher announced it will close two studios in Sweden and Canada. It is also delaying or changing the plans for several other projects. The company stated these changes are to help it become more stable and focused after experiencing some challenging years.

Ubisoft shuts down Prince of Persia remake, 6 others as it resets its business

CEO Yves Guillemot called the decision painful but necessary, explaining that Ubisoft is focusing its strategy to better compete in an industry with rising costs and increasing competition for player attention.

When nostalgia isn’t enough anymore

The Prince of Persia remake was supposed to revive one of Ubisoft’s most loved franchises. The original 2003 game helped define modern action-adventure titles and built a loyal fanbase that had been waiting years for its return. So, cancelling it outright has caught many players off guard.

But this decision reflects a bigger reality in gaming right now. New games are taking longer to make, costing more money, and facing higher chances of failure. In response, publishers are leaning into familiar franchises instead of taking risks on new ideas.

Also read: Call of Duty movie in the works as Paramount strikes mega deal with Activision

That’s exactly what Ubisoft is doing. Rather than betting on untested projects, the company is choosing to double down on proven names like Assassin’s Creed, Far Cry, and Rainbow Six games, which it believes can keep generating steady revenue over time.

Ubisoft shuts down Prince of Persia remake, 6 others as it resets its businessUbisoft CEO Yves Guillemot

The market reacted quickly. Ubisoft’s shares dropped sharply after the announcement, suggesting investors are nervous about both the cancellations and the broader health of the business.

What this means for developers at Ubisoft and players

The closing of studios in Stockholm and Halifax will result in more job losses in an industry that is already dealing with layoffs and project cancellations. Several teams working on mobile and new projects are affected, increasing the overall instability in the industry.

Going forward, Ubisoft says it wants to focus on:

  • Large open-world games
  • Live-service titles with regular updates
  • Expanding existing franchises instead of launching new ones
Ubisoft

For players, the biggest impact is immediate: some long-awaited games are simply gone, with no replacements announced. For developers, it’s another reminder that even established studios are no longer immune to sudden project cuts.

Ubisoft says this reset is about survival in a tougher market. Whether it leads to stability or a future with fewer bold ideas is the real question.

The post Ubisoft shuts down Prince of Persia remake, 5 others as it resets its business first appeared on Technext.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26